Deutsche Bank AG Has $675,000 Position in Omeros Co. (OMER)

Deutsche Bank AG reduced its position in shares of Omeros Co. (NASDAQ:OMER) by 33.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,735 shares of the biopharmaceutical company’s stock after selling 30,892 shares during the period. Deutsche Bank AG’s holdings in Omeros were worth $675,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of OMER. Capital Impact Advisors LLC boosted its position in Omeros by 42.6% during the fourth quarter. Capital Impact Advisors LLC now owns 136,570 shares of the biopharmaceutical company’s stock worth $1,581,000 after acquiring an additional 40,815 shares during the last quarter. Geode Capital Management LLC boosted its position in Omeros by 7.5% during the fourth quarter. Geode Capital Management LLC now owns 516,632 shares of the biopharmaceutical company’s stock worth $5,755,000 after acquiring an additional 35,974 shares during the last quarter. Millennium Management LLC boosted its position in Omeros by 844.8% during the fourth quarter. Millennium Management LLC now owns 1,112,584 shares of the biopharmaceutical company’s stock worth $12,394,000 after acquiring an additional 994,829 shares during the last quarter. Legal & General Group Plc boosted its position in Omeros by 12.7% during the fourth quarter. Legal & General Group Plc now owns 8,370 shares of the biopharmaceutical company’s stock worth $93,000 after acquiring an additional 945 shares during the last quarter. Finally, Miramar Capital LLC acquired a new stake in Omeros during the fourth quarter worth approximately $192,000. 49.48% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:OMER opened at $18.64 on Friday. The company has a market cap of $935.53 million, a price-to-earnings ratio of -8.40 and a beta of 3.57. Omeros Co. has a fifty-two week low of $10.30 and a fifty-two week high of $27.00.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.04). The business had revenue of $21.80 million for the quarter, compared to the consensus estimate of $23.18 million. The firm’s revenue for the quarter was up 1271.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.62) earnings per share. As a group, equities analysts expect that Omeros Co. will post -0.63 EPS for the current year.

A number of analysts recently issued reports on OMER shares. ValuEngine lowered shares of Omeros from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 8th. Zacks Investment Research upgraded shares of Omeros from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a research report on Thursday, March 7th. HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Omeros in a research report on Monday, March 4th. Finally, Cantor Fitzgerald initiated coverage on shares of Omeros in a research note on Monday, May 6th. They set an “overweight” rating and a $26.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $26.83.

COPYRIGHT VIOLATION NOTICE: “Deutsche Bank AG Has $675,000 Position in Omeros Co. (OMER)” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2019/05/19/deutsche-bank-ag-has-675000-position-in-omeros-co-omer.html.

Omeros Company Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Recommended Story: Intrinsic Value

Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Co. (NASDAQ:OMER).

Institutional Ownership by Quarter for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.